Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:HTBX
- CUSIP: N/A
- Web: www.heatbio.com
Capitalization:- Market Cap: $21.62 million
- Outstanding Shares: 35,788,000
Average Prices:- 50 Day Moving Avg: $0.53
- 200 Day Moving Avg: $0.67
- 52 Week Range: $0.46 - $3.35
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.73
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $777,132.00
- Price / Sales: 28.97
- Book Value: $0.28 per share
- Price / Book: 2.21
Profitability:- EBIDTA: ($11,530,000.00)
- Net Margins: -1,479.67%
- Return on Equity: -148.01%
- Return on Assets: -96.31%
Debt:- Current Ratio: 2.77%
- Quick Ratio: 2.77%
Misc:- Average Volume: 405,373 shs.
- Beta: 0.78
- Short Ratio: 7.92
Frequently Asked Questions for Heat Biologics (NASDAQ:HTBX)
What is Heat Biologics' stock symbol?
Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."
How were Heat Biologics' earnings last quarter?
Heat Biologics, Inc. (NASDAQ:HTBX) released its quarterly earnings results on Friday, March, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.05. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.13 million. Heat Biologics had a negative net margin of 1,479.67% and a negative return on equity of 148.01%. View Heat Biologics' Earnings History.
Where is Heat Biologics' stock going? Where will Heat Biologics' stock price be in 2017?
3 equities research analysts have issued 1-year target prices for Heat Biologics' stock. Their predictions range from $2.00 to $2.25. On average, they expect Heat Biologics' stock price to reach $2.13 in the next year. View Analyst Ratings for Heat Biologics.
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include Ampio Pharmaceuticals (AMPE), Eleven Biotherapeutics (EBIO), Bellerophon Therapeutics (BLPH), ContraVir Pharmaceuticals (CTRV), Nivalis Therapeutics (ALPN), Catabasis Pharmaceuticals (CATB), Midatech Pharma PLC (MTPH), Inotek Pharmaceuticals Corporation (ITEK), Zosano Pharma Corporation (ZSAN), Orexigen Therapeutics (OREX), Viking Therapeutics (VKTX), Imprimis Pharmaceuticals (IMMY), Redx Pharma PLC (REDX), Auris Medical Holding AG (EARS), Alcobra (ADHD), Proteon Therapeutics (PRTO), Vical Incorporated (VICL) and Pain Therapeutics (PTIE).
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the folowing people:
- Jeffrey Alan Wolf J.D., Chairman of the Board, Chief Executive Officer
- Timothy J. Creech, Chief Financial Officer
- Jeff Tobin Hutchins Ph.D., Chief Operating Officer, Chief Scientific Officer
- Ann A. Rosar, Vice President - Finance, Corporate Secretary
- Anil K. Goyal Ph.D., Vice President - Business Development
- John K. A. Prendergast Ph.D., Director
- Louis C. Bock, Independent Director
- Michael Kharitonov Ph.D., Independent Director
- John P. Monahan Ph.D., Independent Director
- Edward B. Smith III, Independent Director
Who owns Heat Biologics stock?
Who bought Heat Biologics stock? Who is buying Heat Biologics stock?
How do I buy Heat Biologics stock?
Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heat Biologics' stock price today?
One share of Heat Biologics stock can currently be purchased for approximately $0.63.
MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Heat Biologics (NASDAQ:HTBX)Earnings History by Quarter for Heat Biologics (NASDAQ HTBX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/31/2017 | Q4 2016 | ($0.07) | ($0.12) | $0.13 million | $0.12 million | View | N/A |  |
| 11/10/2016 | Q3 2016 | ($0.15) | ($0.08) | | $0.22 million | View | N/A | |
| 8/15/2016 | Q2 | ($0.27) | ($0.17) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.56) | ($0.50) | | | View | N/A | |
| 2/18/2016 | Q4 | ($0.64) | ($0.78) | | | View | N/A | |
| 10/30/2015 | Q3 | ($0.61) | ($0.62) | | | View | N/A | |
| 8/13/2015 | Q2 | ($0.47) | ($0.56) | | | View | N/A | |
| 5/14/2015 | Q1 | ($0.49) | ($0.57) | | | View | N/A | |
| 4/16/2015 | | ($0.49) | ($0.56) | | | View | N/A | |
| 3/27/2015 | Q4 2014 | ($0.44) | ($0.56) | | | View | N/A | |
| 11/14/2014 | Q314 | ($0.35) | ($0.46) | | | View | N/A | |
| 8/14/2014 | Q214 | ($0.38) | ($0.44) | | | View | N/A | |
| 5/13/2014 | Q1 2014 | ($0.38) | ($0.36) | | | View | N/A | |
| 4/1/2014 | | ($0.30) | ($0.55) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Heat Biologics (NASDAQ:HTBX)2017 EPS Consensus Estimate: ($0.16)
2018 EPS Consensus Estimate: ($0.24)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q4 2017 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q1 2018 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q2 2018 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q3 2018 | 1 | ($0.05) | ($0.05) | ($0.05) |
| Q4 2018 | 1 | ($0.05) | ($0.05) | ($0.05) |
(Data provided by Zacks Investment Research)
Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Heat Biologics (NASDAQ:HTBX)Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 8.74%
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/23/2016 | Michael Kharitonov | Director | Buy | 900,000 | $0.75 | $675,000.00 | |
| 5/19/2014 | Jeffrey Alan Wolf | CEO | Buy | 2,500 | $4.13 | $10,325.00 | |
| 5/16/2014 | Paul Belsky | Director | Buy | 2,500 | $4.11 | $10,275.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Heat Biologics (NASDAQ:HTBX)
Latest Headlines for Heat Biologics (NASDAQ:HTBX)
| Source: |
|
| Date | Headline |
|---|
 | Griffin Securities Initiates Coverage on Heat Biologics, Inc. (HTBX)
www.americanbankingnews.com - September 18 at 12:16 AM |
 | Heat Biologics (HTBX) Plans Common Stock Rights Offering - StreetInsider.com
www.streetinsider.com - September 16 at 6:53 PM |
 | Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
finance.yahoo.com - September 16 at 1:09 AM |
| Heat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per Share
www.americanbankingnews.com - September 15 at 7:20 AM |
| Heat Biologics (HTBX) Granted Type C Meeting with FDA to Discuss ... - StreetInsider.com
www.streetinsider.com - September 14 at 8:46 PM |
| Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
finance.yahoo.com - September 14 at 8:46 PM |
 | Heat Biologics (HTBX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:09 AM |
| Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer
finance.yahoo.com - September 13 at 12:06 AM |
| Analyzing Heat Biologics (HTBX) and its Competitors
www.americanbankingnews.com - September 12 at 12:30 PM |
| Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
finance.yahoo.com - September 7 at 7:52 PM |
| Heat Biologics Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 14 at 7:55 PM |
| Heat Biologics, Inc. (NASDAQ:HTBX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 11 at 8:32 PM |
| Zacks: Analysts Anticipate Heat Biologics, Inc. (HTBX) to Announce -$0.10 Earnings Per Share
www.americanbankingnews.com - July 25 at 11:03 AM |
| Heat Biologics, Inc. (NASDAQ:HTBX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 12 at 10:16 PM |
| Heat Biologics Appoints Damien Hallet as Vice President of CMC Development
finance.yahoo.com - July 3 at 7:13 AM |
| Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics
finance.yahoo.com - July 3 at 7:13 AM |
| Heat Bio plans stock split to avoid delisting
finance.yahoo.com - June 30 at 7:45 PM |
| Brokerages Anticipate Heat Biologics, Inc. (HTBX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 29 at 7:48 AM |
| Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award
finance.yahoo.com - June 28 at 7:10 PM |
| Heat Biologics to Present at the 2017 BIO International Convention
finance.yahoo.com - June 12 at 3:40 PM |
| Heat Biologics Inc (HTBX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 10 at 7:48 AM |
 | Heat Biologics, Inc.: Heat Biologics to Present at the 2017 Marcum Microcap Conference
www.finanznachrichten.de - June 7 at 5:20 PM |
| Heat Biologics to Present at the 2017 Marcum Microcap Conference
finance.yahoo.com - June 7 at 10:23 AM |
| Heat Biologics Presents Poster on its Phase 2 Trial Evaluating HS-410 at ASCO Annual Meeting
finance.yahoo.com - June 5 at 10:32 AM |
| Heat Biologics Inc (HTBX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 1 at 12:32 AM |
| Heat Biologics to Present Poster at 2017 ASCO Annual Meeting
finance.yahoo.com - May 30 at 5:38 PM |
| Heat Biologics Inc (HTBX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 27 at 12:58 AM |
| Noble Financial Reaffirms "Buy" Rating for Heat Biologics Inc (HTBX)
www.americanbankingnews.com - May 14 at 8:44 AM |
 | BRIEF-Heat Biologics says net loss for Q1 of 2017 was $3.2 million
www.reuters.com - May 11 at 11:22 PM |
| Form 8-K HEAT BIOLOGICS, INC. For: May 11
www.streetinsider.com - May 11 at 6:21 PM |
| Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017
finance.yahoo.com - May 11 at 6:21 PM |
| Heat Bio pivots, will focus on combination therapies for cancer
finance.yahoo.com - May 11 at 6:21 PM |
| Heat Biologics Inc (HTBX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 11:26 PM |
| Zacks Investment Research Downgrades Heat Biologics Inc (HTBX) to Hold
www.americanbankingnews.com - May 5 at 11:16 PM |
| Positive News Coverage Somewhat Likely to Affect Heat Biologics (HTBX) Stock Price
www.americanbankingnews.com - May 4 at 11:40 AM |
| Heat Bio completes acquisition of Texas company
finance.yahoo.com - May 2 at 4:14 PM |
| Somewhat Positive Press Coverage Likely to Impact Heat Biologics (HTBX) Share Price
www.americanbankingnews.com - May 1 at 7:32 PM |
| Heat Biologics Announces Completion of Acquisition of Pelican Therapeutics - Yahoo Finance
finance.yahoo.com - May 1 at 1:29 PM |
| Heat Biologics Announces Completion of Acquisition of Pelican Therapeutics
finance.yahoo.com - May 1 at 1:29 PM |
| Heat Biologics (HTBX) Receives Daily Media Sentiment Rating of 0.31
www.americanbankingnews.com - April 28 at 12:10 AM |
| Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
finance.yahoo.com - April 26 at 7:34 PM |
| Heat Biologics (HTBX) Given Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 24 at 10:52 AM |
| Heat Biologics (HTBX) Given Media Sentiment Rating of 0.37
www.americanbankingnews.com - April 21 at 4:14 PM |
| Heat Biologics (HTBX) Receiving Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 18 at 6:49 PM |
| Heat Biologics Inc (HTBX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:25 PM |
| Heat Biologics Inc (HTBX) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 7 at 10:07 PM |
| Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 7 at 10:18 AM |
| OncoSec collaboration data 'promising' for embattled Heat Bio
finance.yahoo.com - April 7 at 10:18 AM |
| Heat Biologics Reports Fiscal Year 2016 Financial Results
finance.yahoo.com - March 31 at 5:48 PM |
| HEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - March 31 at 5:48 PM |
Heat Biologics (HTBX) Chart for Thursday, September, 21, 2017
